Pancreatic Cancer Research

ResearcherMie UniversityActive in the last 2 years

Shugo Mizuno

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2253-544X; OpenAlex author ID A5043419190, A5067861967. Sources: OpenAlex.

Their work

Papers
32 (first author 14, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
100
Papers, trials and grants by year

2012: 2 papers · 2013: none · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 3 papers · 2019: 4 papers · 2020: none · 2021: 4 papers · 2022: 5 papers · 2023: 1 paper · 2024: 2 papers · 2025: 7 papers · 2026: 1 paper

Papers 32

  1. Prognostic Significance of Portal Vein Tumor Thrombus in Pancreatic Ductal Adenocarcinoma Treated With Chemoradiotherapy. Last author DOI 10.1002/ags3.70186↗
  2. Patients With Pancreatic Cancer With Synchronous Liver Oligometastasis Show a Significant Long-Term Survival Benefit From Resection Under Specific Conditions: … Co-author DOI 10.1002/jhbp.12181↗
  3. Long-term survival analysis based on tumor location in patients with pancreatic ductal adenocarcinoma who underwent pancreatectomy following neoadjuvant chemor… Last author DOI 10.1007/s00423-025-03609-8↗
  4. Surgical strategies for locally advanced pancreatic cancer following gemcitabine plus S-1-based chemoradiotherapy. First author DOI 10.1016/j.suronc.2025.102269↗
  5. Prognostic impacts of biological and conditional factors in patients with anatomically resectable pancreatic adenocarcinoma treated with preoperative chemoradi… First author DOI 10.1097/md.0000000000042441↗
  6. Tumor Budding Is an Independent Adverse Prognostic Factor of Pancreatic Ductal Adenocarcinoma Patients Treated by Resection After Preoperative Chemoradiotherap… First author DOI 10.1097/mpa.0000000000002440↗
  7. Three Molecular Developmental Pathways of Remnant Pancreatic Cancer After Resection: A Nationwide Project Study of Japan Pancreas Society. Co-author DOI 10.1097/sla.0000000000006444↗
  8. Impact of Surgical Resection After Induction Gemcitabine Plus S-1-Based Chemoradiotherapy in Patients with Locally Advanced Pancreatic Ductal Adenocarcinoma: A… First author DOI 10.3390/cancers17061048↗
  9. Prognostic impact of the distance from the anterior surface to tumor cells in pancreatoduodenectomy with neoadjuvant chemoradiotherapy for pancreatic ductal ad… Co-author DOI 10.1371/journal.pone.0307876↗
  10. Peritoneal washing cytology status as a crucial prognostic determinant in patients with localized pancreatic ductal adenocarcinoma who underwent curative-inten… Last author DOI 10.1371/journal.pone.0309834↗
  11. Extrapancreatic extension is a better adverse prognostic factor than tumor size in patients with localized pancreatic ductal adenocarcinoma treated with chemor… First author DOI 10.1016/j.hpb.2023.06.015↗
  12. Concomitant splenic artery ligation has no preventive effect on left-sided portal hypertension following pancreaticoduodenectomy with the resection of the port… First author DOI 10.1002/ags3.12545↗
  13. Outcomes of lung metastasis from pancreatic cancer: A nationwide multicenter analysis. Co-author DOI 10.1002/jhbp.1127↗
  14. Role of Serum Carcinoma Embryonic Antigen (CEA) Level in Localized Pancreatic Adenocarcinoma: CEA Level Before Operation is a Significant Prognostic Indicator … Last author DOI 10.1097/sla.0000000000004148↗
  15. Predictive risk factors for early recurrence in patients with localized pancreatic ductal adenocarcinoma who underwent curative-intent resection after preopera… Last author DOI 10.1371/journal.pone.0264573↗
  16. Involvement of superior mesenteric vein and superior mesenteric artery is adverse prognostic factors in patients with localized pancreatic ductal adenocarcinom… First author DOI 10.21203/rs.3.rs-2229927/v1↗
  17. Clinical significance and predictors of complete or near-complete histological response to preoperative chemoradiotherapy in patients with localized pancreatic… First author DOI 10.1016/j.pan.2021.08.011↗
  18. Phase I Study of Preoperative Chemoradiotherapy Using Gemcitabine Plus Nab-Paclitaxel for Patients Who Have Localized Pancreatic Ductal Adenocarcinoma With Con… Last author DOI 10.1097/mpa.0000000000001902↗
  19. Left-sided Portal Hypertension After Pancreaticoduodenectomy With Resection of the Portal Vein/Superior Mesenteric Vein Confluence in Patients With Pancreatic … Co-author DOI 10.1097/sla.0000000000003487↗
  20. Improving the Prognosis of Pancreatic Cancer Through Early Detection: Protocol for a Prospective Observational Study. Co-author DOI 10.2196/26898↗
  21. The clinical impact of portal venous patency ratio on prognosis of patients with pancreatic ductal adenocarcinoma undergoing pancreatectomy with combined resec… Co-author DOI 10.1016/j.pan.2019.01.020↗
  22. Comparative Study Between Gemcitabine-Based and Gemcitabine Plus S1-Based Preoperative Chemoradiotherapy for Localized Pancreatic Ductal Adenocarcinoma, With S… First author DOI 10.1097/mpa.0000000000001227↗
  23. Clinical Significance of Plasma Apolipoprotein-AII Isoforms as a Marker of Pancreatic Exocrine Disorder for Patients with Pancreatic Adenocarcinoma Undergoing … Co-author DOI 10.1155/2019/5738614↗
  24. Prognostic Nutritional Index After Chemoradiotherapy Was the Strongest Prognostic Predictor Among Biological and Conditional Factors in Localized Pancreatic Du… First author DOI 10.3390/cancers11040514↗
  25. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. First author DOI 10.1016/j.pan.2017.11.011↗
  26. Clinical Significance of Histological Effect and Intratumor Stromal Expression of Tenascin-C in Resected Specimens After Chemoradiotherapy for Initially Locall… Co-author DOI 10.1097/mpa.0000000000001022↗
  27. Survival Analysis in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Chemoradiotherapy Followed by Surgery According to the International Consensus o… Co-author DOI 10.3390/cancers10030065↗
  28. Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Biopsy Samples Is a Strong Predictor of Cli… First author DOI 10.1097/mpa.0000000000000597↗
  29. Spontaneous Rupture of an Intrasplenic Aneurysm After Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jemermed.2014.11.025↗
  30. Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: significance of th… First author DOI 10.1097/mpa.0000000000000059↗
  31. Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoper… Co-author DOI 10.1007/s00534-011-0440-3↗
  32. Impact of histological response after neoadjuvant chemoradiotherapy on recurrence-free survival in UICC-T3 pancreatic adenocarcinoma but not in UICC-T4. First author DOI 10.1097/mpa.0b013e3182236442↗

Closest collaborators

The 25 strongest of 100 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masashi Kishiwada · 27 shared papers, 2012–2026 · strength 3.54
  2. Aoi Hayasaki · 23 shared papers, 2018–2026 · strength 3.40
  3. Yasuhiro Murata · 25 shared papers, 2012–2026 · strength 3.21
  4. Naohisa Kuriyama · 22 shared papers, 2015–2026 · strength 3.06
  5. Takahiro Ito · 11 shared papers, 2018–2025 · strength 1.93
  6. Kazuyuki Gyoten · 11 shared papers, 2021–2025 · strength 1.78
  7. Shuji Isaji · 19 shared papers, 2012–2023 · strength 1.60
  8. Hiroyuki Sakurai · 15 shared papers, 2012–2022 · strength 1.26
  9. Benson Kaluba · 6 shared papers, 2022–2025 · strength 1.14
  10. Toru Shinkai · 5 shared papers, 2021–2025 · strength 0.80
  11. Miki Usui · 3 shared papers, 2024–2026 · strength 0.74
  12. Hiroyuki Kato · 8 shared papers, 2018–2022 · strength 0.72
  13. Yoshinori Azumi · 6 shared papers, 2018–2019 · strength 0.47
  14. Masatoshi Watanabe · 2 shared papers, 2024–2025 · strength 0.45
  15. Sohei Satoi · 3 shared papers, 2021–2025 · strength 0.44
  16. Masaji Tani · 3 shared papers, 2022–2025 · strength 0.43
  17. Satoshi Hirano · 3 shared papers, 2022–2025 · strength 0.43
  18. Toshiki Rikiyama · 3 shared papers, 2022–2025 · strength 0.43
  19. Itaru Endo · 3 shared papers, 2022–2025 · strength 0.43
  20. Hiroki Yamaue · 3 shared papers, 2021–2025 · strength 0.40
  21. Kenichi Hakamada · 2 shared papers, 2025 · strength 0.32
  22. Shuji Suzuki · 2 shared papers, 2025 · strength 0.32
  23. Masayuki Ohtsuka · 2 shared papers, 2025 · strength 0.32
  24. Tsutomu Fujii · 2 shared papers, 2021–2025 · strength 0.28
  25. Hiroyuki Inoue · 5 shared papers, 2012–2021 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.